This website contains unedited verbatim presentations made by meeting participants and is not an official report of the National Academies. Opinions and statements included in this material are solely those of the individual authors. They have not been verified as accurate, nor do they necessarily represent the views of other participants, the committee, or the National Academies.
October 28-29, 2014
Creating an Environment to Support Investment and Innovation in Synthetic Biology
Read UK Synthetic Biology Leadership Council Summary Report of Meeting
September 18-19, 2014
*Sarah R. Carter, "Synthetic Biology and the U.S. Biotechnology Regulatory System: Challenges and Options"
*Thomas M. Connelly, "Synthetic Biology and Advanced Manufacturing - A Chemical Industry Perspective"
*Floyd Romesberg, "Artificial DNA in Living Cells"
*Frank F. Weichold, "FDA Oversight of Synthetic Biology"
March 13, 2014
2nd Meeting: Understanding Risk Frameworks for Emerging Technologies
Palo Alto, CA
*Lynne P. Cooper, "Pre-Quantitative Risk: The Social Construction of Risk in Project Teams"
"Adam Finkel, "Channeling Synthetic Biology Through 'Solution-Focused Risk Assessment'"
*Stephen Hilgartner, "The Politics of Risk"
*Sheila Jasanoff, "International Approaches to Risk (Understanding Risk Frameworks for Emerging Technologies)"
*Jennifer Kuzma, "Beyond Old Debates: New Systems Risk Analysis (NESRA) in an Action Oriented Approach"
*Andrew D. Maynard, "Innovative Approaches to Emergent Risks"
*Jonathan Wiener, "Learning from Research about Risk Regulation"
October 20-21, 2013
*Linda Chrisey, "Office of Naval Research Synthetic Biology"
*Denver Dale, "Specialized Capital Formation and Deployment to Support Synthetic Biology"
*Philip Dormitzer, "Synthetic Vaccinology at Novartis"
*Antony Evans, "Glowing Plant"
*Theresa Good, "NSF Investments in Synthetic Biology"
*Alicia Jackson, "Engineering Biology"
*Megan Palmer, "Enabling Next Generation Synthetic Biology Leadership"
*Alan Pearson, The Role of USDA-APHIS in the Regulation of Biotechnology in the United States"
*Pablo Rabinowicz, "DOE Office of Biological and Environmental Research (BER) Genomic Science Program: Biosystems Design"
*Marc Salit, "National Institute of Standards and Technology"
*Mark Segal, "EPA Oversight of Synthetic Biology"
*William So, "Synthetic Biology and National Security"
August 16, 2013
The Evolving Nature of Synthetic Biology: A Panel Discussion on Key Science, Policy, and Societal Challenges Facing the International Community
*Drew Endy, "What and Why Is Synthetic Biology"
*Richard Johnson, "Synthetic Biology: Ten Policy Reasons It Matters to U.S. Foreign Policy"
*Eleonore Pauwels, "Lost in Translation: Sharing Knowledge on the Technological Frontier"
August 1, 2013
This meeting was closed in its entirety.
July 15-16, 2013
Ownership and Sharing: Setting the Patent Framework for Innovation in Synthetic Biology, A Workshop
*Robert Wells, Synthetic Biology and the Bioeconomy
*Rob Carlson, The Bioeconomy, IP, and Synthetic Biology
*Rochelle C. Dreyfuss, The Patent Landscape: Recent Decisions from the U.S. Supreme Court
*Linda Kahl, How Synthetic Biology Challenges Current Patenting/Ownership Frameworks
*Joanne Kamens, Addgene: A Unique Non-Profit Biotech
*Drew Endy, From Genetic Engineering to Synthetic Biology
*Lionel Clarke, Synthetic Biology Ownership and Innovation: Industry and Other Perspectives
*Stephen Laderman, Case Study: Agilent Technologies - Freedom to Operate
Summaries of the proceedings of forum activities may be published as NRC reports.
Vicki L. Chandler (NAS)
Dean of Natural Sciences
Minerva Schools at Keck Graduate Institute
Richard M. Murray (NAE)
Thomas E. and Doris Everhart Professor of Control and Dynamical Systems and Bioengineering
California Institute of Technology
Steven A. Benner
The Foundation for Applied Molecular Evolution (Ffame)
Jef D. Boeke (NAS)
Institute for Systems Genetics
New York University Langone School of Medicine
R. Alta Charo (NAM)
Warren P. Knowles Professor of Law and Bioethics
Department of Medical History and Bioethics
School of Medicine and Public Health
University of Wisconsin-Madison
Laura K. Donohue
Professor of Law
Georgetown University Law Center
Assistant Professor, Bioengineering
The BioBricks Foundation
Richard A. Johnson
Chief Executive Officer
Senior Research Fellow
Department of Social Science, Health and Medicine
Kings College London
Darlene J.S. Solomon
Senior Vice President and Chief Technology Officer
Ex Officio Members:
Office of Naval Research
Office of the Science and Technology Adviser to the Secretary
U.S. Department of State
National Institute of General Medical Sciences
National Institute of Standards and Technology
Jessica M. Tucker
National Institute of Biomedical Imaging and Bioengineering
Supervisory Special Agent
Federal Bureau of Investigation
This project was initially sponsored by the Alfred P. Sloan Foundation and Agilent Technologies. It has subsequently been sponsored by the National Institute of Biomedical Imaging and Bioengineering, the U.S. Department of Homeland Security, and the Federal Bureau of Investigation.